Holen Sie sich die Stockscreener-App
6.99
6.68%
-0.50
Handel nachbörslich:
7.02
0.03
+0.43%
Schlusskurs vom Vortag:
$7.49
Offen:
$7.48
24-Stunden-Volumen:
507.05K
Relative Volume:
1.22
Marktkapitalisierung:
$341.74M
Einnahmen:
$251.00K
Nettoeinkommen (Verlust:
$-87.07M
KGV:
-1.9693
EPS:
-3.5494
Netto-Cashflow:
$-80.18M
1W Leistung:
-18.82%
1M Leistung:
-40.61%
6M Leistung:
+28.02%
1J Leistung:
+132.23%
1-Tages-Spanne:
$6.90
$7.49
1-Wochen-Bereich:
$6.90
$8.64
52-Wochen-Spanne:
$2.71
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Firmenname
Artiva Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 267-4467
Adresse
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
6.99 | 341.74M | 251.00K | -87.07M | -80.18M | -3.5494 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Eingeleitet | Jefferies | Buy |
| 2024-08-13 | Eingeleitet | Needham | Buy |
| 2024-08-13 | Eingeleitet | TD Cowen | Buy |
| 2024-08-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Artiva Biotherapeutics, Inc. (ARTV) Stock Price, News, Quote & History - Yahoo! Finance Canada
ARTV: Phase III NK cell therapy for refractory RA shows high efficacy, safety, and scalable delivery - TradingView
Artiva Biotherapeutics at Stifel forum: nk cell therapy gains traction - Investing.com India
Artiva Biotherapeutics at Stifel forum: nk cell therapy gains traction By Investing.com - Investing.com Canada
Artiva Biotherapeutics Announces Oral Presentation of - GlobeNewswire
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to S&P Global BMI Index - marketscreener.com
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
Artiva Biotherapeutics (NASDAQ: ARTV) Grants CEO Aslan Fred 315,000 Derivative Securities and 110,000 Shares - Kalkine Media
Artiva Biotherapeutics (NASDAQ: ARTV) Grants RA Capital Management 16,250 Derivative Securities - Kalkine Media
Artiva Biotherapeutics (NASDAQ: ARTV) Increases 2024 Equity Incentive Plan by Over 5 Million Shares - Kalkine Media
Artiva Biotherapeutics Grants President Miralles Gines Diego 45,000 Shares at No Cost (NASDAQ: ARTV) - Kalkine Media
Director gets 16,250 stock options at $10.42 at Artiva (ARTV) - Stock Titan
Artiva Biotherapeutics CTOO Christopher Horan Granted RSUs and Stock Options - Kalkine Media
Artiva (ARTV) boosts R&D head's stake with 135K new options - Stock Titan
Artiva Biotherapeutics Expands Equity Plan, Elects Directors - TipRanks
Shareholders back more stock awards at Artiva (ARTV) - Stock Titan
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Biotech Keeps Spending in CheckFiscal Year Earnings - careplusvn.com
Artiva Biotherapeutics (ARTV) CEO Fred Aslan Sells 23,429 Shares - GuruFocus
Artiva Biotherapeutics CEO Fred Aslan Executes Sale of 23,429 Shares Under 10b5-1 Plan - Kalkine Media
ARTV: Pivotal phase III trial in refractory RA advances, aiming for first-in-class deep B-cell depletion - TradingView
Artiva Biotherapeutics at cantor healthcare conference: ra push gains ground By Investing.com - Investing.com Canada
ARTV: Pivotal phase III trial for refractory RA advances, with robust enrollment and data updates expected - TradingView
Artiva Biotherapeutics CEO Aslan Fred Offloads 61,888 Shares at $11.16 on September 3, 2026 (NASDAQ: ARTV) - Kalkine Media
Artiva Biotherapeutics CTO Horan Christopher Disposes of 10,366 Shares at $11.16 Each (NASDAQ: ARTV) - Kalkine Media
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com Canada
Artiva initiates phase 3 trial for refractory arthritis therapy - Investing.com
Artiva Biotherapeutics Provides Update On Planned Allonk® Data Disclosures And Development Milestones For The Remainder Of 2026 - TradingView
Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis - Quiver Quantitative
Artiva Biotherapeutics Provides Update on Planned AlloNK® - GlobeNewswire
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CEO Fred Aslan Sells 61,888 Shares in Tax-Related Sell-to-Cover Transaction - Kalkine Media
Artiva Biotherapeutics COO Jennifer Bush Executes Share Sale for Tax Withholding Purposes - Kalkine Media
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - WBOC TV
Artiva Biotherapeutics (ARTV) Dips 0.44% to $11.25, Hovering Near Key SupportWave Equality - careplusvn.com
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Australia
Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan - Kalkine Media
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressROA Comparison - dars.gov.et
ARTV Q2 2026 Earnings: Slightly Narrower Loss Delivers a Modest BeatConsensus Forecast Report - dars.gov.et
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan - Bitget
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.63 per ShareLow Growth Earnings - dars.gov.et
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Expense Discipline for Clinical-Stage Developer - careplusvn.com
Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat
Finanzdaten der Artiva Biotherapeutics Inc-Aktie (ARTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):